| |
| Xpention
Genetics, Inc. is
a biotechnology company that was formed to develop both immunological
and molecular tests for cancer detection in animals and humans
as well as therapeutic vaccines and other treatment methods
for both veterinary and human cancers. Xpention through its
subsidiary has licensed, exclusive rights to a specific genetic
marker called the p65 that has highly specific correlation
to numerous cancers. |
|
 |
| |
|
|
| |
|
Solution |
| |
|
|
|
|
Xpention, through its wholly-owned subsidiary, has the
rights to a genetic marker in the blood called, P65. P65 is a promising
marker for the early detection of malignant tumor formation and
a useful tool for monitoring therapy and remission. Levels of p65
also appear to have a direct correlation to tumor mass/size. Initially,
the Company will utilize its licensed technology to develop an immunological
test for the detection of cancer in canines. The
development stage is anticipated to last approximately six to eight
months. Following development of the immunological test, the Company
will seek to commercialize the test through licensing the test
to third parties for sale and distribution.
Simultaneously, the Company will utilize its licensed technology
to develop a molecular assay for detection of cancer in
both humans and canines. The molecular test will be a
more sensitive test and can initially be used both as a confirmation
test as well as providing
an ongoing measure of therapeutic success in canines and ultimately
for cancer screening in humans. The duration of the development
stage for the molecular assay is anticipated to be approximately
twelve months. Upon successful development of the molecular
assay, the Company will also seek to commercialize the molecular
test. |
|
